Advances in biomarker testing, analytical methods, and real-world datasets (RWD) that include biomarker and clinical data are rapidly enhancing precision oncology, enabling both forward and reverse translation and allowing for more effective patient-specific treatments.
These innovations play a crucial role in drug development, as well as clinical, payor, and regulatory decision making. However, it’s crucial to consider the strengths and limitations of different approaches and datasets when designing analyses and interpreting precision oncology data.
This report summarizes a Precision Medicine Online webinar, sponsored by Flatiron Health, in which a panel of experts explored the evolving state of precision oncology research and the pivotal role that high-quality linked clinical and multiomic real-world data (RWD) plays in accelerating all stages of drug development to maximize the success of novel therapeutics. On the panel were Professor Charu Aggarwal, director of precision medicine innovation at the University of Pennsylvania Center for Cancer Care Innovation; Milan Radovich, chief scientific officer at Caris Life Sciences; and Neal Meropol, vice president of research oncology at Flatiron Health.
Offered Free by: Flatiron Health
See All Resources from: Flatiron Health
